Sharan Kimberly Rai, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gout | 18 | 2024 | 621 | 2.890 |
Why?
|
Diet, Vegetarian | 1 | 2024 | 180 | 0.820 |
Why?
|
Gout Suppressants | 6 | 2019 | 177 | 0.660 |
Why?
|
Diet, Mediterranean | 2 | 2023 | 740 | 0.640 |
Why?
|
Allopurinol | 5 | 2019 | 198 | 0.560 |
Why?
|
Cost of Illness | 2 | 2017 | 1936 | 0.530 |
Why?
|
Polymyositis | 1 | 2015 | 75 | 0.500 |
Why?
|
Dermatomyositis | 1 | 2015 | 258 | 0.400 |
Why?
|
Hospital Costs | 1 | 2017 | 947 | 0.370 |
Why?
|
Hyperuricemia | 3 | 2019 | 222 | 0.370 |
Why?
|
Arthritis, Rheumatoid | 6 | 2018 | 3763 | 0.350 |
Why?
|
Lupus Erythematosus, Systemic | 4 | 2018 | 2155 | 0.340 |
Why?
|
Cause of Death | 4 | 2017 | 3683 | 0.340 |
Why?
|
Diet, Carbohydrate-Restricted | 2 | 2023 | 262 | 0.330 |
Why?
|
British Columbia | 3 | 2019 | 241 | 0.310 |
Why?
|
Uric Acid | 5 | 2021 | 807 | 0.300 |
Why?
|
Disability Evaluation | 1 | 2015 | 1836 | 0.300 |
Why?
|
Atherosclerosis | 1 | 2023 | 3408 | 0.280 |
Why?
|
Drug Eruptions | 2 | 2019 | 335 | 0.250 |
Why?
|
Rheumatic Diseases | 3 | 2018 | 649 | 0.250 |
Why?
|
Hospitalization | 5 | 2019 | 10721 | 0.230 |
Why?
|
Hypertension | 4 | 2021 | 8540 | 0.230 |
Why?
|
Antirheumatic Agents | 4 | 2018 | 1372 | 0.210 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2024 | 12148 | 0.210 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2018 | 3245 | 0.200 |
Why?
|
Health Care Costs | 1 | 2015 | 3242 | 0.190 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15843 | 0.190 |
Why?
|
Incidence | 7 | 2024 | 21355 | 0.180 |
Why?
|
Uricosuric Agents | 2 | 2019 | 30 | 0.180 |
Why?
|
Probenecid | 2 | 2019 | 73 | 0.180 |
Why?
|
Diuretics | 2 | 2020 | 610 | 0.170 |
Why?
|
Health Occupations | 1 | 2020 | 222 | 0.160 |
Why?
|
Glutamic Acid | 1 | 2024 | 1176 | 0.160 |
Why?
|
Obesity | 5 | 2023 | 12947 | 0.150 |
Why?
|
Diet, Fat-Restricted | 1 | 2020 | 329 | 0.150 |
Why?
|
Gene Frequency | 1 | 2024 | 3606 | 0.150 |
Why?
|
Proportional Hazards Models | 6 | 2018 | 12463 | 0.150 |
Why?
|
Middle Aged | 25 | 2024 | 220920 | 0.140 |
Why?
|
Sulfinpyrazone | 1 | 2016 | 15 | 0.140 |
Why?
|
Population Growth | 1 | 2016 | 50 | 0.140 |
Why?
|
Aged | 21 | 2024 | 169310 | 0.130 |
Why?
|
Spondylitis, Ankylosing | 1 | 2017 | 155 | 0.130 |
Why?
|
Poisson Distribution | 1 | 2017 | 504 | 0.130 |
Why?
|
Colchicine | 1 | 2016 | 259 | 0.120 |
Why?
|
Male | 26 | 2024 | 360842 | 0.120 |
Why?
|
Myocardial Infarction | 1 | 2015 | 11461 | 0.120 |
Why?
|
Comorbidity | 4 | 2016 | 10508 | 0.120 |
Why?
|
Hydroxychloroquine | 1 | 2018 | 426 | 0.110 |
Why?
|
Risk Factors | 9 | 2024 | 74213 | 0.110 |
Why?
|
Stevens-Johnson Syndrome | 1 | 2016 | 246 | 0.110 |
Why?
|
Stroke | 1 | 2015 | 9758 | 0.110 |
Why?
|
Adiposity | 1 | 2023 | 1879 | 0.110 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2016 | 339 | 0.110 |
Why?
|
Diet Surveys | 1 | 2017 | 1162 | 0.110 |
Why?
|
Primary Prevention | 1 | 2020 | 1186 | 0.110 |
Why?
|
Medication Adherence | 2 | 2015 | 2176 | 0.100 |
Why?
|
Humans | 34 | 2024 | 761572 | 0.100 |
Why?
|
Female | 25 | 2024 | 392686 | 0.100 |
Why?
|
Alcohol Drinking | 3 | 2020 | 4028 | 0.100 |
Why?
|
Ophthalmology | 1 | 2018 | 550 | 0.100 |
Why?
|
Databases, Factual | 8 | 2018 | 7967 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2016 | 771 | 0.090 |
Why?
|
Cohort Studies | 10 | 2020 | 41493 | 0.090 |
Why?
|
Follow-Up Studies | 7 | 2023 | 39107 | 0.090 |
Why?
|
Prospective Studies | 4 | 2024 | 54426 | 0.090 |
Why?
|
Adult | 13 | 2024 | 221203 | 0.080 |
Why?
|
Cardiovascular Diseases | 4 | 2020 | 15501 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2017 | 12059 | 0.080 |
Why?
|
Myocardial Ischemia | 1 | 2019 | 2113 | 0.080 |
Why?
|
Risk | 2 | 2017 | 9610 | 0.070 |
Why?
|
Pilot Projects | 1 | 2021 | 8633 | 0.070 |
Why?
|
Disease Management | 1 | 2018 | 2508 | 0.070 |
Why?
|
Linear Models | 1 | 2017 | 5872 | 0.070 |
Why?
|
Glucocorticoids | 1 | 2016 | 2161 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2273 | 0.070 |
Why?
|
Prevalence | 3 | 2019 | 15732 | 0.070 |
Why?
|
Autoimmune Diseases | 1 | 2018 | 2244 | 0.070 |
Why?
|
Survival Rate | 2 | 2017 | 12725 | 0.060 |
Why?
|
gamma-Glutamylcyclotransferase | 1 | 2024 | 11 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2024 | 15936 | 0.060 |
Why?
|
Coronary Artery Disease | 1 | 2024 | 6403 | 0.060 |
Why?
|
Glutamate-Ammonia Ligase | 1 | 2024 | 75 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26127 | 0.060 |
Why?
|
United States | 6 | 2024 | 72335 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14607 | 0.060 |
Why?
|
Health Personnel | 1 | 2017 | 3335 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 1 | 2024 | 17904 | 0.050 |
Why?
|
Survival Analysis | 1 | 2015 | 10090 | 0.050 |
Why?
|
Brain Ischemia | 1 | 2015 | 3049 | 0.050 |
Why?
|
Nutrition Surveys | 2 | 2019 | 1733 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2016 | 2947 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5492 | 0.050 |
Why?
|
Risk Assessment | 3 | 2024 | 23996 | 0.050 |
Why?
|
Carbohydrates | 1 | 2023 | 390 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7391 | 0.050 |
Why?
|
Body Mass Index | 4 | 2020 | 12954 | 0.050 |
Why?
|
Depression | 1 | 2020 | 8124 | 0.040 |
Why?
|
Propensity Score | 2 | 2017 | 1913 | 0.040 |
Why?
|
Prognosis | 2 | 2018 | 29629 | 0.040 |
Why?
|
Israel | 1 | 2020 | 726 | 0.040 |
Why?
|
Drug Dosage Calculations | 1 | 2018 | 117 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5841 | 0.040 |
Why?
|
Diet, Reducing | 1 | 2020 | 485 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10766 | 0.030 |
Why?
|
Mortality | 2 | 2018 | 2901 | 0.030 |
Why?
|
Fruit | 1 | 2021 | 1160 | 0.030 |
Why?
|
Vegetables | 1 | 2021 | 1195 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 11670 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2024 | 2735 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2021 | 2079 | 0.030 |
Why?
|
Eating | 1 | 2021 | 1539 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2024 | 22176 | 0.030 |
Why?
|
Alzheimer Disease | 1 | 2015 | 8601 | 0.030 |
Why?
|
Weight Gain | 1 | 2023 | 2348 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1112 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2017 | 64684 | 0.030 |
Why?
|
Retinal Diseases | 1 | 2018 | 705 | 0.020 |
Why?
|
Reminder Systems | 1 | 2015 | 388 | 0.020 |
Why?
|
Sex Distribution | 1 | 2016 | 2281 | 0.020 |
Why?
|
Age Distribution | 1 | 2016 | 2880 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2017 | 80646 | 0.020 |
Why?
|
Self Report | 1 | 2020 | 3725 | 0.020 |
Why?
|
Weight Loss | 1 | 2020 | 2684 | 0.020 |
Why?
|
Life Style | 1 | 2020 | 3917 | 0.020 |
Why?
|
Anxiety Disorders | 1 | 2020 | 2720 | 0.020 |
Why?
|
Overweight | 1 | 2019 | 2417 | 0.020 |
Why?
|
Aged, 80 and over | 3 | 2019 | 58986 | 0.020 |
Why?
|
Young Adult | 3 | 2019 | 59255 | 0.020 |
Why?
|
Body Weight | 1 | 2018 | 4618 | 0.020 |
Why?
|
Osteoarthritis | 1 | 2015 | 1063 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16592 | 0.020 |
Why?
|
Insulin Resistance | 1 | 2020 | 3963 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10553 | 0.020 |
Why?
|
Mental Health | 1 | 2020 | 3250 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2019 | 2243 | 0.020 |
Why?
|
Anxiety | 1 | 2020 | 4573 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2319 | 0.010 |
Why?
|
Logistic Models | 1 | 2018 | 13255 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18398 | 0.010 |
Why?
|
Diet | 1 | 2019 | 8075 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 6180 | 0.010 |
Why?
|
Smoking | 1 | 2016 | 9053 | 0.010 |
Why?
|
Pregnancy | 1 | 2016 | 29876 | 0.010 |
Why?
|
Animals | 1 | 2023 | 168467 | 0.010 |
Why?
|
Adolescent | 1 | 2018 | 88324 | 0.010 |
Why?
|